Cellanyx, LLC products

Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is rising dramatically in the U.S. due to widespread mammography and the adoption of MRI which has led to dramatic increase in the incidence rates of carcinoma in situ.